



Marksans Pharma Ltd.

The Bombay Stock Exchange Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (E), Mumbai- 400 051

30th May, 2016

Sub: Audited Annual Financial Results for the financial year ended
31st March, 2016 and Auditors Report thereon

Dear Sir,

In terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, enclosed herewith kindly find Audited Annual Financial Results of the Company for the Financial Year ended 31st March, 2016 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today, i.e., 30th May, 2016 along with the Auditors Reports thereon.

In this connection, we hereby certify that the Auditors have given their reports on the Audited Annual Financial Results of the Company for the Financial Year ended 31st March, 2016 (both Standalone and Consolidated) with unmodified opinion.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed: as above

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

Tel.: 022-26200030
7208011789
Mob.: 9892640589

Office No. 620, 6th Floor, Pearl Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West), Mumbai - 400 058.
E-mail : nkmittalandassociates@gmail.com / nkm@nkmittal.com / ca_mittal@rediffmail.com • Website : www.nkmittal.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

Auditor's Report on Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of MARKSANS PHARMA LIMITED

1. We have audited the Financial Results ("the Statement") of **MARKSANS PHARMA LIMITED** ("the Company") for the Year ended 31st March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement, which is the responsibility of the Company's management has been prepared in accordance with recognition and measurement principles laid down in accounting standards as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express an opinion on this Statement based on our audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, this Statement:
 - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) Give a true and fair view of the net profit and other financial information for the year ended 31st March, 2016.

For N. K. MITTAL & ASSOCIATES.

Chartered Accountants

Firm Registration No.113281 W

N.K. Mittal

Proprietor

Membership No. 046785

Place : Mumbai

Date : 30th May 2016





N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

Tel.: 022-26200030
7208011789
Mob.: 9892640589

Office No. 620, 6th Floor, Pearl Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West), Mumbai - 400 058.
E-mail : nkmittalandassociates@gmail.com / nkm@nkmittal.com / ca_mittal@rediffmail.com • Website : www.nkmittal.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

Auditor's Report on Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of MARKSANS PHAMA LIMITED

1. We have audited the Consolidated Financial Results ("the Statement") of **MARKSANS PHARMA LIMITED** ("the Company") for the year ended 31st March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Company's management has been prepared in accordance with recognition and measurement principles laid down in accounting standards as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express an opinion on this Statement based on our audit.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit the financial statements of 3 subsidiaries included in the consolidated financial results, whose consolidated financial statements reflect total assets (before intra-group eliminations) of Rs. 4282.87 Millions as at 31st March, 2016; as well as the total revenue (before intra-group eliminations) of Rs. 5353.74 Millions for the year ended 31 March 2016. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the consolidated financial results for the year ended 31 March 2016, to the extent they have been derived from such financial statements is based solely on the report of such other auditors.
4. In our opinion and to the best of our information and according to the explanations given to us and upon consideration of report of the auditors referred in paragraph 3 above, the Statement:
 - (i) includes the results of the entities listed in Note 3 to the Statement.
 - (ii) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard: and
 - (iii) give a true and fair view of the consolidated net profit and other financial information for the year ended 31st March, 2016.

For N. K. MITTAL & ASSOCIATES.

Chartered Accountants

Firm Registration No. 113281 W

N. K. Mittal

Proprietor

Membership No. 046785

Place : Mumbai

Date : 30 May 2016



MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Grandeur Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai-400053 [CIN: L24110MH1992PLC066364]

Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2016

(₹ in Million)

Sr. No.	PARTICULARS	STANDALONE					CONSOLIDATED	
		3 Months Ended			Current Year ended	Previous Year ended	Current Year ended	Previous Year ended
		31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015	31.03.2016	31.03.2015
		(AUDITED)	(UNAUDITED)	(AUDITED)	(AUDITED)	(AUDITED)	(AUDITED)	(AUDITED)
1	Income							
a)	Net Sales/ Income from Operations (Net of excise duty)	694.30	692.95	917.38	3,581.32	4,055.94	8,933.26	7,966.88
b)	Other Operating Income	63.88	-	30.88	86.87	30.88	88.67	33.43
	Total Income from operations (net)	758.18	692.95	948.26	3,668.19	4,086.82	9,021.93	8,000.31
2	Expenses							
a)	Cost of Material Consumed	381.31	237.44	496.12	1,567.23	1,935.64	3,412.70	2,777.44
b)	Purchase of Stock - in- trade	30.72	30.04	32.19	172.97	232.33	1,635.84	1,689.95
c)	Changes in inventories of finished goods, work-in-process and stock-in- trade	9.12	19.94	(13.62)	41.65	13.55	48.40	(13.00)
d)	Employee benefits expense	89.29	63.78	70.62	261.30	236.55	1,224.17	726.06
e)	Depreciation and amortisation expense	43.91	40.25	24.14	147.48	90.31	281.27	161.34
f)	Other expenses	111.49	153.98	154.90	499.23	480.46	1,249.49	939.23
	Total Expenses	665.84	545.43	764.35	2,689.86	2,988.84	7,851.87	6,281.02
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	92.34	147.52	183.91	978.33	1,097.98	1,170.06	1,719.29
4	Other Income	-	-	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	92.34	147.52	183.91	978.33	1,097.98	1,170.06	1,719.29
6	Finance cost	8.22	13.99	15.00	62.04	131.13	101.55	160.45
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	84.12	133.53	168.91	916.29	966.85	1,068.51	1,558.84
8	Exceptional items	-	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	84.12	133.53	168.91	916.29	966.85	1,068.51	1,558.84
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	33.28	(6.35)	45.85	201.43	295.76	241.08	439.21
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	50.84	139.88	123.06	714.86	671.09	827.43	1,119.63
12	Less: Extraordinary Item	-	-	-	-	-	-	-
13	Net Profit/ (Loss) for the period (11-12)	50.84	139.88	123.06	714.86	671.09	827.43	1,119.63
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	42.31	25.67
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	50.84	139.88	123.06	714.86	671.09	785.12	1,093.96
17	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	409.31	409.31	409.31	409.31	409.31*
18	Reserve Excluding Revaluation Reserve	-	-	-	3,692.67	3,047.46	4,008.93	3,263.32
19 a)	Earnings Per Share (before extraordinary items- ₹)- Basic	0.12	0.34	0.30	1.75	1.64	2.02	2.74
	Diluted	0.12	0.34	0.30	1.75	1.64	2.02	2.74
b)	Earnings Per Share(after extraordinary items- ₹)- Basic	0.12	0.34	0.30	1.75	1.64	1.92	2.67
	Diluted	0.12	0.34	0.30	1.75	1.64	1.92	2.67



Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30.05.2016.
- The Board of Directors has recommended dividend of ₹ 0.12 per equity share of ₹ 1/- each face value (i.e. 12%) subject to the approval of shareholders in the ensuing Annual General Meeting.
- The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd, Marksans Pharma (U.K.) Limited and Marksans Pharma Inc. USA.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- The figure for the quarter ended March 31, 2016 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2016 and the unaudited published year to date figure upto December 31, 2015 being the date of the end of the third quarter of the financial year.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- Statement of Assets and Liabilities.

		(₹ in Million)			
	Particulars	Standalone as at		Consolidated as at	
		31.03.2016	31.03.2015	31.03.2016	31.03.2015
		AUDITED	AUDITED	AUDITED	AUDITED
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share capital	534.31	534.31	534.31	534.31
	(b) Reserves and surplus	3,692.67	3,047.46	4,008.93	3,263.32
	(c) Money received against share warrants	-	-	-	-
	Sub-total-Shareholders' funds	4,226.98	3,581.77	4,543.24	3,797.63
2	Minority Interest	-	-	83.61	81.00
3	Non-current liabilities				
	(a) Long-term borrowings	-	-	-	-
	(b) Deferred tax liabilities (Net)	3.12	5.03	-	14.55
	Sub-total - Non-current liabilities	3.12	5.03	-	14.55
4	Current liabilities				
	(a) Short-term borrowings	406.18	435.22	878.93	821.86
	(b) Trade payables	314.08	445.82	1,189.80	1,070.20
	(c) Other current liabilities	6.76	398.81	6.76	398.81
	(d) Short-term provisions	384.87	404.48	518.83	571.50
	Sub-total -Current liabilities	1,111.89	1,684.33	2,594.32	2,862.37
	TOTAL-EQUITY AND LIABILITIES	5,341.99	5,271.13	7,221.17	6,755.55
B	ASSETS				
1	Non-current assets				
	(a) Fixed assets	974.72	900.11	2,696.55	1,658.98
	(b) Non-current investments	2,314.40	676.16	-	-
	(c) Long-term loans and advances	12.48	8.26	104.06	8.26
	(d) Deferred tax Assets (Net)	-	-	19.11	-
	Sub-total - Non-current assets	3,301.60	1,584.53	2,819.72	1,667.24
2	Current assets				
	(a) Inventories	437.38	510.25	1,677.92	1,301.07
	(b) Trade receivables	1,334.15	1,246.30	2,172.93	1,834.54
	(c) Cash and cash equivalents	31.27	1,675.42	353.01	1,852.65
	(d) Short-term loans and advances	237.59	254.63	197.59	100.05
	Sub-total - Current assets	2,040.39	3,686.60	4,401.45	5,088.31
	TOTAL ASSETS	5,341.99	5,271.13	7,221.17	6,755.55



Place: Mumbai.
Date: 30.05.2016
www.marksanspharma.com

For MARKSANS PHARMA LIMITED

MARK SALDANHA
Managing Director.